September 16 - 19, 2015
Sheraton New York Times Square Hotel
New York, New York, USA
Abstract submission deadline: Wednesday, June 10
Advance registration deadline: Monday, July 27
The Reference Meeting for Scientists, Clinicians, Regulators, Drug Developers, and Patient Advocates
September 16-19, 2015Sheraton New York Times Square HotelNew York, New York
With the explosion of interest in cancer immunotherapy and the proliferation of scientific meetings in the field, the time is right for a coordinated effort hosted by the field's leaders. The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to join forces to sponsor the first International Cancer Immunotherapy Conference. This collaborative meeting will be held every other year, in lieu of each organization's individual meeting, and will alternate between the United States and Europe. We believe that by combining our efforts we can be more effective and efficient in disseminating the latest cutting-edge information.
The inaugural meeting will take place at the Sheraton Times Square in New York City on September 16-19, 2015. Entitled "Translating Science into Survival," it will cover all areas of inquiry in cancer immunology and immunotherapy, including: immune regulation of T cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T cell therapies, checkpoint blockade, biomarkers, combinations, and the microbiome. More than 60 talks by acknowledged leaders in these areas will be given.
This joint meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates. We hope this will be the one cancer immunotherapy meeting that you will be sure to attend in 2015.
Scientific Planning CommitteeJames P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TexasCedrik M. Britten, GlaxoSmithKline, Stevenage, United KingdomGlenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MassachusettsAlexander M. M. Eggermont, Institut Gustave Roussy, Paris, FranceCarl G. Figdor, Radboud University of Nijmegen, Nijmegen, The NetherlandsWolf-Hervé Fridman, Centre de Recherche des Cordeliers, Paris, FrancePhilip D. Greenberg, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WashingtonAxel Hoos, GlaxoSmithKline, Collegeville, PennsylvaniaElizabeth M. Jaffee, Johns Hopkins University, Baltimore, MarylandPeter W. M. Johnson, University of Southampton, Southampton, United KingdomGuido Kroemer, Centre de Recherche des Cordeliers, Paris, FranceNils Lonberg, Bristol-Myers Squibb, Milpitas, CaliforniaCornelis J. M. Melief, Leiden University Medical Center, Leiden, The NetherlandsEllen Puré, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PennsylvaniaRobert D. Schreiber, Washington University, St. Louis, Missouri
Diamond SupporterBristol-Myers SquibbPlatinum SupporterRocheSilver SupportersAmgen GenentechMiltenyi Biotec RegeneronSupportersDoris Duke FoundationGilead Lilly OncologyProfessional Educational GrantsAbbVie AstraZeneca Celgene GenentechGilead Incyte Lilly Merck Novartis
Continuing Medical Education Activity – AMA PRA Category 1 Credits™ available